Moderna Ships First mRNA Vaccines Manufactured in Canada
ByAinvest
Monday, Sep 22, 2025 8:14 am ET1min read
MRNA--
The shipment marks a significant milestone in Canada's domestic vaccine production capacity and strengthens national health security [2]. Stéphane Bancel emphasized that the delivery of the first made-in-Canada mRNA vaccines to provinces and territories across the country is not just about local manufacturing but also about scientific leadership, national health security, and timely access to the latest mRNA medicines.
The drug substance of Moderna's authorized Spikevax® product is manufactured at the facility in Laval, Quebec, while the fill-and-finish of the new single-use pre-filled syringes is completed by Novocol Pharma in Cambridge, Ontario. The vaccine has also received authorization from regulators in the United States, Europe, Japan, Switzerland, and several other countries [2].
The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, noted that this achievement represents a major step for Canada's biomanufacturing and life sciences sector. The government is building a resilient, forward-looking economy that positions Canada as a global leader in scientific research and innovation [2].
The Honourable Marjorie Michel, Minister of Health, highlighted that manufacturing the first-ever doses of a fully made-in-Canada COVID-19 vaccine demonstrates the power of collaboration between government, industry, and science to protect the health of Canadians. By producing vaccines locally, Canada supports its economy while strengthening its ability to respond quickly to future public health emergencies [2].
Canadian Access and Eligibility
Timing and eligibility for the COVID-19 public vaccination program in Canada are set by each province and territory. Those who meet provincial criteria will receive COVID-19 vaccines free of charge. For individuals not covered under the public programs, efforts are ongoing with private insurers and payers to streamline access and reimbursement within the private sector. Canadians are encouraged to consult their provincial or territorial health authorities for the latest information on eligibility and availability [2].
Moderna has shipped its first mRNA vaccines produced entirely in Canada to Canadian provinces and territories. The vaccines, targeting the SARS-CoV-2 LP.8.1 variant, were manufactured in Laval, Quebec, and filled in Cambridge, Ontario. The updated vaccine was approved by Health Canada on August 21, 2025, and has been authorized in several other countries. Moderna CEO Stéphane Bancel notes that this step enhances health security and ensures rapid access to the latest mRNA medicines.
Moderna has shipped its first mRNA vaccines produced entirely in Canada to Canadian provinces and territories. The vaccines, targeting the SARS-CoV-2 LP.8.1 variant, were manufactured in Laval, Quebec, and filled in Cambridge, Ontario. The updated vaccine was approved by Health Canada on August 21, 2025, and has been authorized in several other countries. Moderna CEO Stéphane Bancel notes that this step enhances health security and ensures rapid access to the latest mRNA medicines [1].The shipment marks a significant milestone in Canada's domestic vaccine production capacity and strengthens national health security [2]. Stéphane Bancel emphasized that the delivery of the first made-in-Canada mRNA vaccines to provinces and territories across the country is not just about local manufacturing but also about scientific leadership, national health security, and timely access to the latest mRNA medicines.
The drug substance of Moderna's authorized Spikevax® product is manufactured at the facility in Laval, Quebec, while the fill-and-finish of the new single-use pre-filled syringes is completed by Novocol Pharma in Cambridge, Ontario. The vaccine has also received authorization from regulators in the United States, Europe, Japan, Switzerland, and several other countries [2].
The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, noted that this achievement represents a major step for Canada's biomanufacturing and life sciences sector. The government is building a resilient, forward-looking economy that positions Canada as a global leader in scientific research and innovation [2].
The Honourable Marjorie Michel, Minister of Health, highlighted that manufacturing the first-ever doses of a fully made-in-Canada COVID-19 vaccine demonstrates the power of collaboration between government, industry, and science to protect the health of Canadians. By producing vaccines locally, Canada supports its economy while strengthening its ability to respond quickly to future public health emergencies [2].
Canadian Access and Eligibility
Timing and eligibility for the COVID-19 public vaccination program in Canada are set by each province and territory. Those who meet provincial criteria will receive COVID-19 vaccines free of charge. For individuals not covered under the public programs, efforts are ongoing with private insurers and payers to streamline access and reimbursement within the private sector. Canadians are encouraged to consult their provincial or territorial health authorities for the latest information on eligibility and availability [2].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet